Maria Anderson

A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors.

Roy S. Herbst, Michael S. Gordon, Gregg Fine et al. · Journal of Clinical Oncology · 2013 · 191 citations

Pharmacy, Oncology, Pharmacotherapy +17

Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)

Jérôme Fayette, Lori J. Wirth, Cristina Oprean et al. · Frontiers in Oncology · 2016 · 106 citations · Full text

Medicine, Oncology, Pharmacology +17

A phase Ib dose escalation study of the OX40 agonist MOXR0916 and the PD-L1 inhibitor atezolizumab in patients with advanced solid tumors.

Jeffrey R. Infante, Aaron R. Hansen, Michael J. Pishvaian et al. · Journal of Clinical Oncology · 2016 · 78 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Biomarkers and associations with the clinical activity of PD-L1 blockade in a MPDL3280A study.

John D. Powderly, Hartmut Koeppen, F. Stephen Hodi et al. · Journal of Clinical Oncology · 2013 · 54 citations

Medicine, Immunology, Oncology +17

Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer

Rocio García‐Carbonero, Eric Van Cutsem, Fernando Rivera et al. · The Oncologist · 2017 · 28 citations · Full text

Medicine, Oncology, Pharmacology +16